Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied –– Achieved Statistical Significance with Up to 48% Slowing of Clinical ...

Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.

从中医的角度来看，多系统萎缩的发病与人体内部的气血、脏腑等有着密切关系。中医认为，肾为先天之本，主藏精、主骨生髓 ...

Shares of Alterity Therapeutics soared 108% premarket Thursday, surging toward levels last seen in September 2022, with trading volume nearly 75 times the daily average. The clinical-stage biotech ...

Alterity Therapeutics (NASDAQ:ATHA) announced Thursday that its lead candidate, ATH434, slowed clinical progression with a ...

Alterity Therapeutics shares are moving higher on Thursday after the company reported positive topline results from its Phase 2 clinical trial of ATH434 in early-stage multiple system atrophy.

脊髓小脑性共济失调8型（Spinocerebellar Ataxia Type 8，简称SCA8）是一种由13号染色体上ATXN8OS基因的重复扩增引起的罕见遗传性神经退行性疾病。尽管SCA8的发病率相对较低，但其临床表现的多样性却给患者的诊断和治疗带来了挑战。

For example, annualized rates of atrophy of MSA, parkinsonian variant, are 1.0% for the whole brain (controls 0.4%) but can be as high as 4.5% in the pons (controls 0.2%) or 3.2% in cerebellum ...

Following “positive” top-line phase II trial results, neurodegenerative disease house Alterity Therapeutics (ASX:ATH) will ...

CurePSP announced the recipients of their Collaborative Approaches to Resources, Education and Support (CARES) grants designed to advance best practices in the care of progressive supranuclear palsy ...

Alterity Therapeutics (NASDAQ: ATHE) shares moved up at warp-speed Thursday, on announcing positive topline results from the ATH434-201 randomized, double-blind, placebo-controlled Phase 2 clinical ...

Alterity Therapeutics (ATHE) announced topline results from the ATH434-201 randomized, double-blind, placebo-controlled Phase 2 clinical trial ...